TCM-Mesh: The database and analytical system for network pharmacology analysis for TCM preparations

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Zhang, Run Zhi ^a   Yu, Shao Jun ^a   Bai, Hong ^a   Ning, Kang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

CHEMISTRY; CHINESE MEDICINE; DRUG COMBINATION; FACTUAL DATABASE; HUMAN; METABOLISM; PANAX; PHARMACOLOGY; TRENDS;

DATABASES, FACTUAL; DRUG COMBINATIONS; HUMANS; MEDICINE, CHINESE TRADITIONAL; PANAX; PHARMACOLOGY; PROTEINS;

EID: 85020620937     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-03039-7     Document Type: Article

References (81)

1. Yi, Y. D. & Chang, I. M. An overview of traditional Chinese herbal formulae and a proposal of a new code system for expressing the formula title. Evid. Based Complement. Alternat. Med 1, 125-132 (2004).
2. Chan, K. Progress in traditional Chinese medicine. Trends Pharmacol. Sci. 16, 182-187 (1995).
3. Corson, T. W. & Crews, C. M. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130, 769-774 (2007).
4. Qiu, J. Traditional medicine: a culture in the balance. Nature 448, 126-128 (2007).
5. Boh, B. Ganoderma lucidum: a potential for biotechnological production of anti-cancer and immunomodulatory drugs. Recent Pat. Anticancer Drug Discov 8, 255-287 (2013).
6. Boh, B., Berovic, M., Zhang, J. & Zhi-Bin, L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol. Annu. Rev 13, 265-301 (2007).
7. Ma, H. T., Hsieh, J. F. & Chen, S. T. Anti-diabetic effects of Ganoderma lucidum. Phytochemistry 114, 109-113 (2015).
8. Paterson, R. R. Ganoderma - a therapeutic fungal biofactory. Phytochemistry 67, 1985-2001 (2006).
9. Kim, J. H. Cardiovascular diseases and Panax ginseng: a review on molecular mechanisms and medical applications. J Ginseng Res 36, 16-26 (2012).
10. Chan, G. H. et al. Ginseng extracts restore high-glucose induced vascular dysfunctions by altering triglyceride metabolism and downregulation of atherosclerosis-related genes. Evid. Based Complement. Alternat. Med 2013, 797310 (2013).
11. Lee, S. T., Chu, K., Sim, J. Y., Heo, J. H. & Kim, M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 22, 222-226 (2008).
12. Yuan, H. D., Kim, J. T., Kim, S. H. & Chung, S. H. Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 36, 27-39 (2012).
13. Rhee, Y. H., Lee, S. P., Honda, K. & Inoue, S. Panax ginseng extract modulates sleep in unrestrained rats. Psychopharmacology (Berl.) 101, 486-488 (1990).
14. Leung, K. W. & Wong, A. S. Pharmacology of ginsenosides: a literature review. Chin. Med 5, 20 (2010).
15. Xie, B. et al. An approach based on HPLC-fingerprint and chemometrics to quality consistency evaluation of Liuwei Dihuang Pills produced by different manufacturers. J. Pharm. Biomed. Anal. 48, 1261-1266 (2008).
16. Zhao, X., Wang, Y. & Sun, Y. Quantitative and qualitative determination of Liuwei Dihuang tablets by HPLC-UV-MS-MS. J. Chromatogr. Sci. 45, 549-552 (2007).
17. Wang, P. et al. Thyroxine and reserpine-induced changes in metabolic profiles of rat urine and the therapeutic effect of Liu Wei Di Huang Wan detected by UPLC-HDMS. J. Pharm. Biomed. Anal. 53, 631-645 (2010).
18. Wu, C. R., Lin, L. W., Wang, W. H. & Hsieh, M. T. The ameliorating effects of LiuWei Dihuang Wang on cycloheximide-induced impairment of passive avoidance performance in rats. J. Ethnopharmacol. 113, 79-84 (2007).
19. An, X. F., Zhao, Y. & Yu, J. Y. Treatment of Early Diabetic Retinopathy by Liuwei Dihuang Pill Combined Ginkao Leaf Tablet. Chin J Integr Trad West Med 36, 674-677 (2016).
20. Hu, S. J., Fang, Q., Liu, J. S., Zhang, L. & Cao, E. Z. Clinical study on intervention of liuwei dihuang pill on hormonotherapy in treating nephrotic syndrome. Chin J Integr Trad West Med 25, 107-110 (2005).
21. Lin, L., Wang, Q., Yi, Y., Wang, S. & Qiu, Z. Liuwei Dihuang Pills enhance the effect of western medicine in treating diabetic nephropathy: a meta-analysis of randomized controlled trials. Evid. Based Complement. Alternat. Med 2016, 1509063 (2016).
22. Song, X. Y., Chen, Q. & Qi, X. Y. Effect of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients. Chin J Integr Trad West Med 24, 1087-1090 (2004).
23. Wang, J. et al. Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid. Based Complement. Alternat. Med 2012, 714805 (2012).
24. Zheng, W. C., Hu, S. J. & Fang, Q. Intervention of liuwei dihuang pill on lupus nephropathy treated with cylophosphamide and glucocorticoids. Chin J Integr Trad West Med 25, 983-985 (2005).
25. Xu, Z. Modernization: One step at a time. Nature 480, S90-92 (2011).
26. Li, S. Network target: a starting point for traditional Chinese medicine network pharmacology. Chin J Chin Mater Med 36, 2017-2020 (2011).
27. Li, S., Zhang, B. & Zhang, N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst. Biol. 5(Suppl 1), S10 (2011).
28. Li, S., Fan, T. P., Jia, W., Lu, A. & Zhang, W. Network pharmacology in traditional chinese medicine. Evid. Based Complement. Alternat. Med 2014, 138460 (2014).
29. Li, S. & Zhang, B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med 11, 110-120 (2013).
30. Liang, X., Li, H. & Li, S. A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study. Mol Biosyst 10, 1014-1022 (2014).
31. Banerjee, P. et al. Super Natural II-a database of natural products. Nucleic Acids Res 43, D935-939 (2015).
32. Chen, C. Y. TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS One 6, e15939 (2011).
33. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40, D1100-1107 (2012).
34. Xue, R. et al. TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res 41, D1089-1095 (2013).
35. Kuhn, M. et al. STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res 42, D401-407 (2014).
36. Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447-452 (2015).
37. Hamosh, A. et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 30, 52-55 (2002).
38. Becker, K. G., Barnes, K. C., Bright, T. J. & Wang, S. A. The genetic association database. Nat. Genet. 36, 431-432 (2004).
39. Wexler, P. TOXNET: an evolving web resource for toxicology and environmental health information. Toxicology 157, 3-10 (2001).
40. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
41. Kuhn, M. & Letunic, I. The SIDER database of drugs and side effects. Nucleic Acids Res 44, D1075-1079 (2016).
42. Rao-Rao, L.I., Zhang, Z.J., Wang, Z.J., Wang, F. & Yuan, S.T. Literature Analysis on Toxicity, Side Effect and Adverse Reaction of Traditional Chinese Medicine. Chin J Exp Tradit Med Form (2010).
43. Kuhn, M., von Mering, C., Campillos, M., Jensen, L. J. & Bork, P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 36, D684-688 (2008).
44. von Mering, C., Jensen, L. J. & Snel, B. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 33, D433-437 (2005).
45. Andre, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343-2351 (2004).
46. Francini, G. et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106, 899-906 (1994).
47. Terjung, A., Kummer, S. & Friedrich, M. Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer. Anticancer Res. 34, 7233-7238 (2014).
48. Briegel, J. et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin. Investig. 72, 782-787 (1994).
49. Melikhova, N. I., Mura'vev, Iu. V. & Sigidin, Ia. A. Effectiveness of intra-articular dimexide in combination with hydrocortisone and hydrocortisone in patients with juvenile rheumatoid arthritis. Klin. Med. (Mosk.) 67, 103-105 (1989).
50. Masuishi, T. et al. Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clin. Colorectal Cancer (2016).
51. Pavlakis, N. et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J. Clin. Oncol. 34, 2728-2735 (2016).
52. Larsen, F. O. et al. Capecitabine and oxaliplatin before, during, and after radiotherapy for high-risk rectal cancer. Clin. Colorectal Cancer (2016).
53. Das, K. M. Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol. Clin. North Am. 18, 1-20 (1989).
54. Dworski, R., Fitzgerald, G. A., Oates, J. A. & Sheller, J. R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med. 149, 953-959 (1994).
55. Harati, Y. & Patten, B. M. Prednisone use in concurrent autoimmune diseases. Arch. Neurol. 36, 103-106 (1979).
56. Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34, D668-672 (2006).
57. Grauballe, M. B., Ostergaard, J. A., Schou, S., Flyvbjerg, A. & Holmstrup, P. Effects of TNF-alpha blocking on experimental periodontitis and type 2 diabetes in obese diabetic Zucker rats. J. Clin. Periodontol. 42, 807-816 (2015).
58. Hao, W. & Friedman, A. Mathematical model on Alzheimer's disease. BMC Syst. Biol. 10, 108 (2016).
59. Jin, Y. H. & Kim, S. A. 2-Methoxycinnamaldehyde inhibits the TNF-alpha-induced proliferation and migration of human aortic smooth muscle cells. Int. J. Mol. Med. (2016).
60. Nepal, S. et al. Abresham ameliorates dyslipidemia, hepatic steatosis and hypertension in high-fat diet fed rats by repressing oxidative stress, TNF-alpha and normalizing NO production. Exp. Toxicol. Pathol. 64, 705-712 (2012).
61. Tocci, G. et al. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opin. Drug Saf. 15, 55-61 (2016).
62. de la Monte, S. M., Jhaveri, A., Maron, B. A. & Wands, J. R. Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery. J. Neuropathol. Exp. Neurol. 66, 272-283 (2007).
63. Mazzotti, D. R. et al. Adenosine deaminase polymorphism affects sleep EEG spectral power in a large epidemiological sample. PLoS One 7, e44154 (2012).
64. Rupp, T. L., Wesensten, N. J., Newman, R. & Balkin, T. J. PER3 and ADORA2A polymorphisms impact neurobehavioral performance during sleep restriction. J. Sleep Res. 22, 160-165 (2013).
65. Annes, J. P. et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet beta-cell replication. Proc. Natl. Acad. Sci. USA 109, 3915-3920 (2012).
66. Boison, D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev. 65, 906-943 (2013).
67. Khosrowbeygi, A., Shiamizadeh, N. & Taghizadeh, N. Maternal circulating levels of some metabolic syndrome biomarkers in gestational diabetes mellitus. Endocrine 51, 245-255 (2016).
68. Liu, Y. X. et al. Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro. J. Ethnopharmacol. 166, 168-175 (2015).
69. Ye, J. et al. Chemical fingerprinting of Liuwei Dihuang Pill and simultaneous determination of its major bioactive constituents by HPLC coupled with multiple detections of DAD, ELSD and ESI-MS. J. Pharm. Biomed. Anal. 49, 638-645 (2009).
70. Abhary, S., Hewitt, A. W., Burdon, K. P. & Craig, J. E. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 58, 2137-2147 (2009).
71. Abu Seman, N. et al. Genetic, epigenetic and protein analyses of intercellular adhesion molecule 1 in Malaysian subjects with type 2 diabetes and diabetic nephropathy. J. Diabetes Complications 29, 1234-1239 (2015).
72. Freeman, W. M. et al. A multistep validation process of biomarkers for preclinical drug development. Pharmacogenomics J. 10, 385-395 (2010).
73. Gu, H. F., Ma, J., Gu, K. T. & Brismar, K. Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. Front. Endocrinol. (Lausanne) 3, 179 (2012).
74. Ellina, O. et al. Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFNgamma) in type 1 diabetes mellitus nephropathy. Clin. Chem. Lab. Med 50, 167-174 (2012).
75. Lin, F. L., Shen, H. C., Zhu, B. & Lin, K. Q. Effects of simvastatin on expression of CTGF and alpha-SMA in renal tubulointerstitium of rats with diabetic nephropathy. Chin J Nat Med 39, 511-516 (2010).
76. Turk, T. et al. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J. Histochem. Cytochem. 57, 623-631 (2009).
77. Wang, J. et al. Downregulation of miR-30c promotes renal fibrosis by target CTGF in diabetic nephropathy. J. Diabetes Complications 30, 406-414 (2016).
78. Ali, S. M., Khalifa, H., Mostafa, D. K. & El Sharkawy, A. Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus. Life Sci. 153, 180-187 (2016).
79. Donia, M. S. & Fischbach, M. A. HUMAN MICROBIOTA. Small molecules from the human microbiota. Science 349, 1254766 (2015).
80. O'Boyle, N. M. et al. Open Babel: an open chemical toolbox. J. Cheminform. 3, 33 (2011).
81. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).